# **Announcement Summary**

# **Entity name**

MGC PHARMACEUTICALS LTD

## **Announcement Type**

New announcement

### Date of this announcement

23/12/2022

# The Proposed issue is:

Total number of +securities proposed to be issued for a placement or other type of issue

| ASX +security code | +Security description | Maximum Number of<br>+securities to be issued |
|--------------------|-----------------------|---|
| MXCAAA             | CONVERTIBLE NOTES     | 586,432                                       |

# Proposed +issue date

28/12/2022

Refer to next page for full details of the announcement

## Part 1 - Entity and announcement details

\_\_\_\_

#### 1.1 Name of +Entity

### MGC PHARMACEUTICALS LTD

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

## 1.2 Registered Number Type

**Registration Number** 

ABN

30116800269

1.3 ASX issuer code

MXC

1.4 The announcement is

☑ New announcement

1.5 Date of this announcement

23/12/2022

1.6 The Proposed issue is:

A placement or other type of issue

## Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis? ☑ No

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? Existing class

Will the proposed issue of this +security include an offer of attaching +securities? ☑ No

Details of +securities proposed to be issued

## ASX +security code and description

MXCAAA: CONVERTIBLE NOTES

Number of +securities proposed to be issued

586,432

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid?

What is the issue price per

+security?

AUD - Australian Dollar AUD 1.36400

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes



| Dort | 70  | Timetable | _ |
|------|-----|-----------|---|
| Раπ  | 70- | rimetabi  | е |

7C.1 Proposed +issue date

28/12/2022

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? 
☑ Yes

**7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1** 5/10/2022

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? 

⟨♥ No.

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? 
⊗ No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?  $\ensuremath{\mathfrak{C}}$  No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue? 

☑ No

7E.2 Is the proposed issue to be underwritten? 

☑ No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

## Part 7F - Further Information

# 7F.01 The purpose(s) for which the entity is issuing the securities

Funds raised will primarily be used for working capital requirements

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?  $\ensuremath{\mathfrak{G}}$  No

7F.2 Any other information the entity wishes to provide about the proposed issue